BioArctic AB (publ), a Swedish research-based biopharma company, announced that the first patient has been dosed with exidavnemab in the EXIST phase 2a study, in Parkinson’s disease patients ... key ...
A new laboratory study in mice suggests that primates like humans evolved large brains with a helping hand from microbes that ...
The new Marie Skłodowska-Curie Doctoral Network AIPD is dedicated to investigating artificial intelligence methods to combat Parkinson's disease. It ...
The lab of Hassane Mchaourab, director of the Center for Applied Artificial Intelligence in Protein Dynamics and professor of ...
The company is hoping to show GT-02287 can slow Parkinson's progression by restoring function of GCase, an enzyme encoded by ...
Pooled data analysis of efficacy and safety from Phase 2b and Phase 3 data sets in patients with early-stage Parkinson’s ...
Detailed price information for Denali Therapeutics Inc (DNLI-Q) from The Globe and Mail including charting and trades.
A team of international researchers led by Professor Johan Jakobsson at Lund University has secured a 52 million SEK grant from the Aligning Science ...
A research team led by Professor Cho Il-joo of the convergence medicine class at Korea University School of Medicine ...
In a Switzerland study, two people with spinal cord injuries received deep brain stimulation therapy and were able to walk without assistance and even climb stairs.
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first patient has been dosed with exidavnemab in the EXIST Phase 2a study, in Parkinson's disease patients. Exidavnemab is a ...
Home-baked cupcakes made by Sue Thomas, a member of the local branch to mark the branch’s 39th anniversary (Image: Parkinson's UK) The group meets regularly on the fourth Tuesday of each month at St ...